Asset Details
Do you wish to reserve the book?
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Do you wish to request the book?
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
2021
Overview
Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor. In enzymatic and cell-based assays, saracatinib preferentially inhibited ALK2, compared with other receptors of the BMP/TGF-β signaling pathway, and induced dorsalization in zebrafish embryos consistent with BMP antagonism. We further tested the efficacy of saracatinib using an inducible ACVR1Q207D-transgenic mouse line, which provides a model of heterotopic ossification (HO), as well as an inducible ACVR1R206H-knockin mouse, which serves as a genetically and physiologically faithful FOP model. In both models, saracatinib was well tolerated and potently inhibited the development of HO, even when administered transiently following soft tissue injury. Together, these data suggest that saracatinib is an efficacious clinical candidate for repositioning in FOP treatment, offering an accelerated path to clinical proof-of-efficacy studies and potentially significant benefits to individuals with this devastating condition.
Publisher
American Society for Clinical Investigation,American Society for Clinical investigation
Subject
Activin Receptors, Type I - antagonists & inhibitors
/ Activin Receptors, Type I - genetics
/ Animals
/ Benzodioxoles - pharmacology
/ Benzodioxoles - therapeutic use
/ Bone Morphogenetic Proteins - drug effects
/ Bone Morphogenetic Proteins - metabolism
/ Drug Evaluation, Preclinical
/ Embryos
/ Kinases
/ Ligands
/ Mice
/ Mutation
/ Myositis Ossificans - genetics
/ Myositis Ossificans - metabolism
/ Myositis Ossificans - pathology
/ Ossification, Heterotopic - genetics
/ Ossification, Heterotopic - metabolism
/ Ossification, Heterotopic - pathology
/ Proteins
/ Quinazolines - therapeutic use
